BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 28917266)

  • 1. Urinary biomarkers in prostate cancer detection and monitoring progression.
    Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
    Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
    Filella X; Foj L
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary Biomarkers for Prostate Cancer.
    Tosoian JJ; Ross AE; Sokoll LJ; Partin AW; Pavlovich CP
    Urol Clin North Am; 2016 Feb; 43(1):17-38. PubMed ID: 26614026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
    Schmid M; Hansen J; Chun FK
    Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.
    Cao DL; Ye DW; Zhang HL; Zhu Y; Wang YX; Yao XD
    Prostate; 2011 May; 71(7):700-10. PubMed ID: 20957673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative biomarkers for prostate cancer early diagnosis and progression.
    You J; Cozzi P; Walsh B; Willcox M; Kearsley J; Russell P; Li Y
    Crit Rev Oncol Hematol; 2010 Jan; 73(1):10-22. PubMed ID: 19328712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary RNA-based biomarkers for prostate cancer detection.
    Martignano F; Rossi L; Maugeri A; Gallà V; Conteduca V; De Giorgi U; Casadio V; Schepisi G
    Clin Chim Acta; 2017 Oct; 473():96-105. PubMed ID: 28807541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
    Sardana G; Dowell B; Diamandis EP
    Clin Chem; 2008 Dec; 54(12):1951-60. PubMed ID: 18927246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current biomarkers for diagnosing of prostate cancer.
    Stephan C; Jung K; Ralla B
    Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in proteomic prostate cancer biomarker discovery.
    Goo YA; Goodlett DR
    J Proteomics; 2010 Sep; 73(10):1839-50. PubMed ID: 20398807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
    Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
    Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary biomarkers of prostate cancer.
    Fujita K; Nonomura N
    Int J Urol; 2018 Sep; 25(9):770-779. PubMed ID: 30129068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
    Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
    Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen and other serum and urine markers in prostate cancer.
    Stephan C; Ralla B; Jung K
    Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.